162 related articles for article (PubMed ID: 38701304)
1. Cost-effectiveness of medication therapy management among Medicare population and across racial/ethnic groups.
Tsang CCS; Wang J; Shih YT
Medicine (Baltimore); 2024 May; 103(18):e37935. PubMed ID: 38701304
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Medication Therapy Management Program Across Racial and Ethnic Groups Among Medicare Beneficiaries.
Tsang CCS; Shih YT; Dong X; Garuccio J; Browning JA; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Zeng R; Wang J
Value Health; 2023 May; 26(5):649-657. PubMed ID: 36376143
[TBL] [Abstract][Full Text] [Related]
3. Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.
Wang J; Qiao Y; Shih YC; Jarrett-Jamison J; Spivey CA; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Manag Care Spec Pharm; 2015 Nov; 21(11):993-1003. PubMed ID: 26521111
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.
Spivey CA; Wang J; Qiao Y; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Manag Care Spec Pharm; 2018 Feb; 24(2):97-107. PubMed ID: 29384031
[TBL] [Abstract][Full Text] [Related]
5. Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria.
Wang J; Qiao Y; Tina Shih YC; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC
Res Social Adm Pharm; 2014; 10(1):106-25. PubMed ID: 23759673
[TBL] [Abstract][Full Text] [Related]
6. Racial/ethnic disparities in the enrollment of Medication Therapy Management programs among Medicare beneficiaries with Alzheimer's disease and related dementias.
Browning JA; Tsang CCS; Zeng R; Dong X; Garuccio J; Wan JY; Chisholm-Burns MA; Finch CK; Tsao JW; Wang J
Curr Med Res Opin; 2022 Oct; 38(10):1715-1725. PubMed ID: 35852087
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups.
Spivey CA; Qiao Y; Wang J; Shih YT; Wan JY; Dagogo-Jack S; Cushman WC; Hines LE; Chisholm-Burns MA
J Am Geriatr Soc; 2019 Mar; 67(3):581-587. PubMed ID: 30674080
[TBL] [Abstract][Full Text] [Related]
8. Effects of Medicare comprehensive medication review on racial/ethnic disparities in nonadherence to statin medications among patients with Alzheimer's Disease: an observational analysis.
Browning JA; Tsang CCS; Dong X; Wan JY; Chisholm-Burns MA; Finch CK; Tsao JW; Liu C; Wang J
BMC Health Serv Res; 2022 Feb; 22(1):159. PubMed ID: 35130899
[TBL] [Abstract][Full Text] [Related]
9. Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population.
Wang J; Brown LM; Hong SH
J Am Pharm Assoc (2003); 2012; 52(5):e87-96. PubMed ID: 23023863
[TBL] [Abstract][Full Text] [Related]
10. Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma.
Lu D; Qiao Y; Johnson KC; Wang J
J Asthma; 2017 Jun; 54(5):504-513. PubMed ID: 27676212
[TBL] [Abstract][Full Text] [Related]
11. Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program.
Allen A; Hung A
J Manag Care Spec Pharm; 2024 Jun; 30(6):609-616. PubMed ID: 38824629
[TBL] [Abstract][Full Text] [Related]
12. Racial and ethnic disparities in Medicare Part D medication therapy management services utilization.
Dong X; Tsang CCS; Browning JA; Garuccio J; Wan JY; Shih YCT; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Wang J; Wang J
Explor Res Clin Soc Pharm; 2023 Mar; 9():100222. PubMed ID: 36712831
[TBL] [Abstract][Full Text] [Related]
13. Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence.
Dong X; Tsang CCS; Zhao S; Wan JY; Shih YT; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Hines LE; Wang J
Am Health Drug Benefits; 2021 Sep; 14(3):101-109. PubMed ID: 35261713
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Socioeconomic and Geographical Characteristics of Beneficiaries Receiving a Comprehensive Medication Review.
Chou J; Pellegrin K; Cooke CE; Zarowitz B; Hanlon A; Lozano A; Brandt NJ
J Manag Care Spec Pharm; 2020 Oct; 26(10):1276-1281. PubMed ID: 32996388
[TBL] [Abstract][Full Text] [Related]
15. Effects of medicare part d on disparity implications of medication therapy management eligibility criteria.
Wang J; Qiao Y; Shih YC; Jamison JJ; Spivey CA; Li L; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
Am Health Drug Benefits; 2014 Sep; 7(6):346-58. PubMed ID: 25558303
[TBL] [Abstract][Full Text] [Related]
16. Historical trend of disparity implications of Medicare MTM eligibility criteria.
Wang J; Qiao Y
Res Social Adm Pharm; 2013; 9(6):758-69. PubMed ID: 23062785
[TBL] [Abstract][Full Text] [Related]
17. Economic assessment of changes to an existing medication therapy management program of a large regional health plan.
Peasah SK; Hammonds T; Liu Y; Campbell V; Manolis C; Good CB
J Manag Care Spec Pharm; 2021 Feb; 27(2):147-156. PubMed ID: 33506728
[No Abstract] [Full Text] [Related]
18. Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population.
Wang J; Surbhi S; Zhang Z; Spivey CA; Chisholm-Burns M
Res Social Adm Pharm; 2014; 10(6):904-917. PubMed ID: 25458405
[TBL] [Abstract][Full Text] [Related]
19. Assessing Medicare beneficiaries' willingness-to-pay for medication therapy management services.
Woelfel JA; Carr-Lopez SM; Delos Santos M; Bui A; Patel RA; Walberg MP; Galal SM
Consult Pharm; 2014 Feb; 29(2):104-9. PubMed ID: 24513420
[TBL] [Abstract][Full Text] [Related]
20. Effects of Medicare Part D medication therapy management on racial/ethnic disparities in adherence to antidementia medications among patients with Alzheimer's disease and related dementias: An observational study.
Dong X; Tsang CCS; Wan JY; Chisholm-Burns MA; Finch CK; Tsao JW; Browning JA; Garuccio J; Zeng R; Wang J
Explor Res Clin Soc Pharm; 2024 Mar; 13():100420. PubMed ID: 38420610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
